2000-2020年澳大利亚致死性加巴喷丁类相关中毒的特征
该研究为2000-2020年澳大利亚全国回顾性病例系列,从国家死因信息系统检索所有加巴喷丁类(加巴喷丁或普瑞巴林)作为 contributory mechanism 的药物毒性死亡,共887例。平均年龄45.7岁,男性55.2%,意外中毒81.3%、故意18.7%。普瑞巴林占92.9%,血药浓度中位数7.6 mg/L(范围0.1-850.0 mg/L);加巴喷丁占7.2%,中位数9.5 mg/L(范围0.5-1940.0 mg/L)。99.8%检出其他药物,最常见阿片类(90.1%)、催眠镇静药(76.9%)、抗抑郁药(60.5%)。临床意义:致死性加巴喷丁类中毒几乎均合并其他中枢抑制剂,单纯加巴喷丁类致死少见,急诊/ICU应重点识别合并用药与基础疾病。
要点
- 887例致死性加巴喷丁类相关中毒中,99.8%合并其他药物,阿片类占90.1%、催眠镇静药76.9%、抗抑郁药60.5%。
- 普瑞巴林占92.9%,血药浓度中位数7.6 mg/L(范围0.1-850.0 mg/L);加巴喷丁占7.2%,中位数9.5 mg/L(范围0.5-1940.0 mg/L)。
- 意外中毒占81.3%,故意中毒占18.7%;19.5%病例中基础疾病对药物毒性有共同作用。
- 45.4%病例BMI处于肥胖范围,常见临床显著基础病包括心脏增大24.9%、肺气肿20.2%、肾硬化18.7%、重度肝脂肪变性11.7%。
- 精神健康问题、慢性疼痛和物质滥用突出;5例同时检出普瑞巴林和加巴喷丁,未检出其他加巴喷丁类。
适用人群与场景
- 2000-2020年澳大利亚全国所有因药物毒性死亡且加巴喷丁类(加巴喷丁或普瑞巴林)为 contributory mechanism 的病例,来自国家死因信息系统;原文未提及具体纳入/排除标准、急诊/ICU/院前场景或病情阶段。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 致死性加巴喷丁类相关中毒中99.8%合并其他药物,阿片类占90.1%、催眠镇静药76.9%、抗抑郁药60.5%,需警惕合并中枢抑制剂导致的呼吸抑制等致命风险。
研究设计与关键结果
- 研究类型:全国回顾性病例系列;样本量887例;数据来源国家死因信息系统(2000-2020年)。
- 人群:平均年龄45.7岁,男性55.2%;意外中毒81.3%,故意中毒18.7%;19.5%基础疾病对药物毒性有共同作用。
- 暴露:普瑞巴林92.9%,血药浓度中位数7.6 mg/L(范围0.1-850.0 mg/L);加巴喷丁7.2%,中位数9.5 mg/L(范围0.5-1940.0 mg/L);5例同时检出两者。
- 合并用药:99.8%检出其他药物,阿片类90.1%、催眠镇静药76.9%、抗抑郁药60.5%。
- 基础疾病:BMI肥胖范围45.4%,心脏增大24.9%、肺气肿20.2%、肾硬化18.7%、重度肝脂肪变性11.7%。
证据类型、等级与局限
- 证据类型:回顾性全国病例系列;原文未给出证据等级或推荐强度;局限:仅凭死亡证明与尸检毒理学,无法推断因果关系或人群发生率;原文未提及单中心/多中心、样本量计算或前瞻性验证。
对床旁实践的改变
- 在急诊/ICU遇到加巴喷丁类中毒时,应常规排查合并用药,尤其是阿片类、催眠镇静药和抗抑郁药,因原文显示99.8%病例检出其他药物。
- 对加巴喷丁类相关中毒患者,应评估基础疾病(心脏增大、肺气肿、肾硬化、重度肝脂肪变性)及肥胖,因原文显示这些情况常见且19.5%对药物毒性有共同作用。
- 原文未提供特异性解毒剂、剂量调整或血液净化推荐,不能由本文得出具体治疗阈值或干预措施。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Gabapentinoids are centrally active GABA agonists whose use has increased substantially in the past decade. The current study aimed to provide a comprehensive clinical profile of a national case series of fatal poisonings related to gabapentinoids.
METHODS: Retrospective study of all deaths due to drug toxicity in Australia in which gabapentinoids were a contributory mechanism, retrieved from the National Coronial Information System (2000-2020). Information was collected on case characteristics, toxicology and major organ pathology.
RESULTS: A total of 887 cases were identified, with a mean age of 45.7 years and 55.2% being male. Death was due to accidental toxicity in 81.3% of cases and intentional in 18.7%. Pre-existing disease was co-contributory to drug toxicity in 19.5%. Pregabalin was present in 92.9% of cases, with a median blood concentration of 7.6 mg/L (range 0.1-850.0 mg/L). Gabapentin was present in 7.2%, with a median blood concentration of 9.5 mg/L (range 0.5-1940.0 mg/L). Both pregabalin and gabapentin were present in five cases. No other gabapentinoids were detected. Drugs other than gabapentinoids were present in 99.8%, most frequently opioids (90.1%), hypnosedatives (76.9%) and antidepressants (60.5%). A body mass index in the obese range was seen in 45.4%. Clinically significant pre-existing disease was common, notably cardiomegaly (24.9%), emphysema (20.2%), nephrosclerosis (18.7%) and severe hepatic steatosis (11.7%).
CONCLUSIONS: The concomitant use of other drugs was close to universal, with CNS depressants predominating. Mental health problems, chronic pain and substance misuse were prominent.
参考来源
- Darke S, Duflou J, Peacock A, et al. Characteristics of fatal gabapentinoid-related poisoning in Australia, 2000-2020. Clin Toxicol (Phila). 2021. PMID: 34402696. doi:10.1080/15563650.2021.1965159
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。